Beyond Biotech - the podcast from Labiotech

How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can …

Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from e…

Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing symptoms – there is, as of yet, no cure. One Finnis…

RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions?

Alnylam was the very first company to translate RNAi from Nobel Prize winning science i…

Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030. 

One of the most common of those m…

The UK is preparing to change the game for healthcare - but why, how, and what will it cost?

Recently the UK government announced plans to sequence the DNA of every baby born in that country. A part o…

Is cultivated meat the future of pet food? And is there a place for cultivated meat on human dinner tables, too?

Traditional agricultural methods are slow, require large tracts of land, significant en…

With supply chain management and optimization, risk management, and the capacity to address global markets efficiently and effectively top of mind for all growing biotechs, I'm excited to be joined b…

Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous s…

Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins o…

The World Health Organization reports that more than 600 million people suffer from lower back pain globally, making it the leading cause of disability worldwide. 

Chronic lower back pain – where the …

Trauma surgeons in Ukraine operating theaters saved lives and limbs thanks to the innovative lab-grown blood vessels from US biotech, Humacyte.

Humacyte is pioneering a platform that enables the inves…

Much of the attention of the biotech industry has been focused on the city of Boston this week as the annual BIO International Convention hit town. 

BIO is the world’s largest partnering conference fo…

What are the most interesting questions in biotech, and is it even possible to find answers to those questions?

Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco B…

When biotechs start fundraising they regularly turn to the venture capital market seeking investment. The pool of VC money can be large, and part of that pool is corporate venture capital. Backed by …

Biotechnology has always been a dynamic domain, but the world of finance that provides the fuel for the fire is just as vibrant. Trying to predict where the market for biotech investment is heading i…

Generative artificial intelligence (GenAI) is already changing how people research, communicate, and interact, but its biggest impacts on biotech are still to come.

Cradle is a Dutch-Swiss biotech sta…

There are cell therapies, gene therapies, and biologics – and then there is Immusoft. 

Immusoft sits at the nexus point of some of the most innovative approaches in biopharma, and their Immune System …

Flagship Pioneering doesn't go out to find the next big thing in biotech when investing their billions in fund capital - instead, they take a different route.

Flagship Pioneering has founded more than…

Are TCR-NK treatments the next big thing in cell therapies for cancer patients?

As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, o…